MD3331900T2 - Peptide și combinație de peptide pentru utilizare în imunoterapie împotriva cancerului de prostată și altor cancere - Google Patents
Peptide și combinație de peptide pentru utilizare în imunoterapie împotriva cancerului de prostată și altor cancereInfo
- Publication number
- MD3331900T2 MD3331900T2 MDE20180586T MDE20180586T MD3331900T2 MD 3331900 T2 MD3331900 T2 MD 3331900T2 MD E20180586 T MDE20180586 T MD E20180586T MD E20180586 T MDE20180586 T MD E20180586T MD 3331900 T2 MD3331900 T2 MD 3331900T2
- Authority
- MD
- Moldova
- Prior art keywords
- peptides
- cells
- combination
- relates
- present
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000005426 pharmaceutical component Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Plant Pathology (AREA)
Abstract
Prezenta invenţie se referă la peptide, proteine, acizi nucleici şi celule pentru utilizare în metode imunoterapeutice. În particular, prezenta invenţie se referă la imunoterapia cancerului. În plus, prezenta invenţie se referă la epitopii peptidici ai celulelor T citotoxice asociate tumorii, singuri sau asociaţi cu alte peptide asociate tumorii, care pot servi, de exemplu, drept componente farmaceutice active ale formulelor de vaccin care stimulează răspunsurile imunitare antitumorale sau pentru stimularea celulelor T ex vivo şi transferarea la pacienţi. Peptidele legate de molecule ale complexului major de histocompatibilitate (MHC), sau peptidele ca atare, pot fi, de asemenea, ţinte ale anticorpilor, ale receptorilor solubili ai celulelor T şi ale altor molecule de legare.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562201289P | 2015-08-05 | 2015-08-05 | |
GBGB1513921.5A GB201513921D0 (en) | 2015-08-05 | 2015-08-06 | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
PCT/EP2016/068727 WO2017021527A2 (en) | 2015-08-05 | 2016-08-05 | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3331900T2 true MD3331900T2 (ro) | 2021-05-31 |
Family
ID=54200350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20180586T MD3331900T2 (ro) | 2015-08-05 | 2016-08-05 | Peptide și combinație de peptide pentru utilizare în imunoterapie împotriva cancerului de prostată și altor cancere |
Country Status (35)
Country | Link |
---|---|
US (24) | US9908920B2 (ro) |
EP (4) | EP3854801A3 (ro) |
JP (3) | JP6884752B2 (ro) |
KR (1) | KR20180035845A (ro) |
CN (2) | CN107849107A (ro) |
AR (1) | AR105817A1 (ro) |
AU (8) | AU2016303021B2 (ro) |
BR (1) | BR112018001687A2 (ro) |
CA (3) | CA3110640A1 (ro) |
CL (7) | CL2018000324A1 (ro) |
CO (1) | CO2018002202A2 (ro) |
CR (6) | CR20200431A (ro) |
CY (1) | CY1123854T1 (ro) |
DK (1) | DK3331900T3 (ro) |
EA (1) | EA201890440A1 (ro) |
ES (1) | ES2862400T3 (ro) |
GB (1) | GB201513921D0 (ro) |
HR (1) | HRP20210709T8 (ro) |
HU (1) | HUE053657T2 (ro) |
IL (2) | IL310078A (ro) |
LT (1) | LT3331900T (ro) |
MA (4) | MA46022B1 (ro) |
MD (1) | MD3331900T2 (ro) |
MX (2) | MX2018001421A (ro) |
PE (1) | PE20180695A1 (ro) |
PH (1) | PH12018500189A1 (ro) |
PL (1) | PL3331900T3 (ro) |
PT (1) | PT3331900T (ro) |
RS (1) | RS61713B1 (ro) |
SG (1) | SG10202001660YA (ro) |
SI (1) | SI3331900T1 (ro) |
TW (2) | TWI829618B (ro) |
UA (1) | UA125816C2 (ro) |
WO (1) | WO2017021527A2 (ro) |
ZA (1) | ZA201800513B (ro) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2508923A (en) * | 2012-12-17 | 2014-06-18 | Bombardier Transp Gmbh | Inductive power transfer system having inductive sensing array |
IL300761A (en) | 2013-08-05 | 2023-04-01 | Immatics Biotechnologies Gmbh | Innovative immunotherapy against several tumors, such as lung cancer, including NSCLC |
GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
CA2994842A1 (en) | 2015-08-05 | 2017-02-09 | Eisai R&D Management Co., Ltd. | Chiral reagents for preparation of homogeneous oligomers |
EP4299136A3 (en) | 2015-12-16 | 2024-02-14 | Gritstone bio, Inc. | Neoantigen identification, manufacture, and use |
JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
KR102639592B1 (ko) | 2016-12-08 | 2024-02-21 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
WO2018213467A1 (en) * | 2017-05-16 | 2018-11-22 | The Johns Hopkins University | Manabodies and methods of using |
HUE057110T2 (hu) | 2017-07-14 | 2022-04-28 | Immatics Biotechnologies Gmbh | Továbbfejlesztett kettõs specifitású polipeptid-molekula |
DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
CN111684062A (zh) | 2018-02-09 | 2020-09-18 | 伊玛提克斯美国公司 | 制造t细胞的方法 |
AU2019276577A1 (en) * | 2018-06-01 | 2021-01-14 | Geneoscopy, Inc. | Detection method |
US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
US11945850B2 (en) * | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
WO2020167894A1 (en) * | 2019-02-12 | 2020-08-20 | Vanderbilt University | Polypeptides for restoring endothelial function and methods of use thereof |
US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
US11975025B2 (en) | 2019-05-27 | 2024-05-07 | Immatics US, Inc. | Viral vectors and use thereof in adoptive cellular therapy |
US20210002610A1 (en) | 2019-06-06 | 2021-01-07 | Immatics US, Inc. | Methods for manufacturing t cells by direct sorting and compositions thereof |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
KR20230012465A (ko) | 2020-02-24 | 2023-01-26 | 이매틱스 유에스 인코포레이티드 | 암 및 관련 악성 종양을 치료하기 위해 t 세포를 확장하는 방법 |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
CA3173666A1 (en) * | 2020-04-14 | 2021-10-21 | Claude Perreault | Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof |
WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
EP4255474A1 (en) * | 2020-12-07 | 2023-10-11 | Iogenetics, LLC. | Personalized immunotherapies |
JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス,アイエヌシー. | Cd8ポリペプチド、組成物、及びそれらの使用方法 |
CA3217739A1 (en) | 2021-05-05 | 2022-11-10 | Sebastian Bunk | Bma031 antigen binding polypeptides |
US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
CN113527435B (zh) * | 2021-07-14 | 2022-06-07 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 对前列腺癌细胞特异性识别的新型多肽及其衍生物与应用 |
WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於t細胞療法之t細胞群體的單核球耗盡 |
WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
FI86437C (fi) | 1978-12-22 | 1992-08-25 | Biogen Inc | Foerfarande foer framstaellning av polypeptider med de antigena egenskaperna hos ett hepatitis b- virusantigen. |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
US9340577B2 (en) * | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
SG49008A1 (en) | 1993-03-05 | 1998-05-18 | Cytel Corp | Hla-a2.1 binding peptides and their uses |
ES2108460T3 (es) | 1993-06-03 | 1997-12-16 | Therapeutic Antibodies Inc | Fragmentos de anticuerpos en terapeutica. |
US20040157780A1 (en) * | 1993-11-29 | 2004-08-12 | Epimmune Inc. | CTL inducing peptides from c-erb2 (HER-2/neu) |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
US6824993B2 (en) * | 1995-06-06 | 2004-11-30 | Human Genome Sciences, Inc. | Antibodies that bind human prostate specific G-protein receptor HPRAJ70 |
JP4767371B2 (ja) | 1996-01-17 | 2011-09-07 | インペリアル・イノベイションズ・リミテッド | 細胞障害性tリンパ球(ctl)を用いた免疫療法 |
US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
AU4086397A (en) * | 1996-09-06 | 1998-03-26 | Centocor Inc. | Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen |
US7008772B1 (en) * | 1997-02-25 | 2006-03-07 | Corixa Corporation | Compounds for immunodiagnosis of prostate cancer and methods for their use |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US20070020327A1 (en) * | 1998-11-10 | 2007-01-25 | John Fikes | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
US7361338B2 (en) | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
EP1220931A1 (en) * | 1999-10-07 | 2002-07-10 | Schering Aktiengesellschaft | Dna encoding prost 07 polypeptide |
WO2001034802A2 (en) * | 1999-11-12 | 2001-05-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
HUP0203968A3 (en) * | 2000-01-14 | 2004-09-28 | Corixa Corp Seattle | Compositions and methods for the therapy and diagnosis of prostate cancer |
AU2001233114A1 (en) * | 2000-02-04 | 2001-08-14 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
US20030219806A1 (en) * | 2000-02-22 | 2003-11-27 | Millennium Pharmaceuticals, Inc. | Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
CA2403909A1 (en) * | 2000-03-27 | 2001-10-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
EP2316950A1 (en) | 2000-03-27 | 2011-05-04 | Technion Research and Development Foundation, Ltd. | Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same |
CA2404541A1 (en) * | 2000-03-31 | 2001-10-11 | Curagen Corporation | G-protein coupled receptors and nucleic acids encoding same |
US7834146B2 (en) * | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
EP2322228B1 (en) | 2000-06-05 | 2018-01-10 | Altor BioScience Corporation | T cell receptor fusion proteins and conjugates and methods of use thereof |
GB0015722D0 (en) * | 2000-06-27 | 2000-08-16 | Smithkline Beecham Sa | Vaccine |
US7199229B2 (en) * | 2000-08-11 | 2007-04-03 | Mount Sinai Hospital | Kallikrein gene |
EP1911461B1 (en) * | 2000-10-19 | 2011-12-07 | Epimmune Inc. | HLA class I and II binding peptides and their uses |
US7048931B1 (en) * | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US7459539B2 (en) * | 2000-12-15 | 2008-12-02 | Agensys, Inc. | Antibody that binds zinc transporter protein 108P5H8 |
WO2002055557A2 (en) * | 2000-12-18 | 2002-07-18 | Curagen Corp | Human proteins and nucleic acids encoding same |
AUPR402201A0 (en) * | 2001-03-27 | 2001-04-26 | Queensland University Of Technology | Polynucleotides and polypeptides linked to cancer and/or benign tumours |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
JP2005533486A (ja) | 2002-02-20 | 2005-11-10 | ダイアックス、コープ | Mhc−ペプチド複合体結合リガンド |
DE10215321A1 (de) * | 2002-04-02 | 2003-10-23 | Metagen Pharmaceuticals Gmbh | Trp-p8 Splice Varianten und regulatorische RNA |
US7569225B2 (en) * | 2002-08-12 | 2009-08-04 | The Council Of The Queensland Institute Of Medical Research | Immunogenic lipopeptides comprising T-helper and B-cell epitopes |
WO2004016643A2 (en) | 2002-08-16 | 2004-02-26 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
PT1558643E (pt) | 2002-11-09 | 2009-08-24 | Immunocore Ltd | Apresentação de um receptor das células t |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
GB0318096D0 (en) * | 2003-08-01 | 2003-09-03 | Queen Mary & Westfield College | Vaccine |
CA2598593A1 (en) * | 2005-02-28 | 2006-09-08 | Nycomed Gmbh | Method for identifying pde11 modulators |
EP1862804B1 (en) * | 2005-03-14 | 2010-05-05 | Link Genomics, Inc. | Method for diagnosis of prostate cancer |
EP1806358B1 (en) | 2005-09-05 | 2010-03-17 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
AU2006308863A1 (en) * | 2005-10-31 | 2007-05-10 | Janssen Pharmaceutica N.V. | A polypeptide complex of TRPM8 and calmodulin and its uses thereof |
US20130332133A1 (en) * | 2006-05-11 | 2013-12-12 | Ramot At Tel Aviv University Ltd. | Classification of Protein Sequences and Uses of Classified Proteins |
US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
WO2009135019A2 (en) | 2008-05-01 | 2009-11-05 | Beth Israel Deaconess Medical Center | Methods and compositions for prostate cancer immunotherapy |
PL2119726T5 (pl) | 2008-05-14 | 2018-04-30 | Immatics Biotechnologies Gmbh | Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu |
WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
US10706955B2 (en) * | 2010-03-23 | 2020-07-07 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
EA029860B1 (ru) * | 2010-07-15 | 2018-05-31 | Олег Ильич ЭПШТЕЙН | Фармацевтическая композиция и способы лечения заболеваний мочеполовой системы |
US20120121592A1 (en) * | 2010-10-13 | 2012-05-17 | Baylor Research Institute | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells |
CA2816225A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
NZ609916A (en) * | 2010-12-14 | 2015-03-27 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
WO2014047085A2 (en) | 2012-09-20 | 2014-03-27 | Rongfu Wang | Prostate-specific tumor antigen and uses thereof |
US20190292535A1 (en) | 2012-11-08 | 2019-09-26 | Roche Diagnostics Operations, Inc. | Nucleic acids encoding chimeric polypeptides for library screening |
EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
TWI636065B (zh) | 2013-08-05 | 2018-09-21 | 伊瑪提克斯生物科技有限公司 | 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物 |
GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
US20180028627A1 (en) * | 2015-02-26 | 2018-02-01 | Bioventures, Llc | Treatment vaccine for prostate cancer |
JP7236216B2 (ja) * | 2015-04-23 | 2023-03-09 | ナントミクス,エルエルシー | がんのネオエピトープ |
GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
EP3648791A1 (en) * | 2017-07-04 | 2020-05-13 | CureVac AG | Novel nucleic acid molecules |
-
2015
- 2015-08-06 GB GBGB1513921.5A patent/GB201513921D0/en not_active Ceased
-
2016
- 2016-08-04 AR ARP160102395A patent/AR105817A1/es unknown
- 2016-08-05 TW TW105124943A patent/TWI829618B/zh active
- 2016-08-05 IL IL310078A patent/IL310078A/en unknown
- 2016-08-05 MA MA46022A patent/MA46022B1/fr unknown
- 2016-08-05 CA CA3110640A patent/CA3110640A1/en active Pending
- 2016-08-05 WO PCT/EP2016/068727 patent/WO2017021527A2/en active Application Filing
- 2016-08-05 HU HUE16750766A patent/HUE053657T2/hu unknown
- 2016-08-05 TW TW109124889A patent/TW202106702A/zh unknown
- 2016-08-05 CA CA3110633A patent/CA3110633A1/en active Pending
- 2016-08-05 CN CN201680045204.4A patent/CN107849107A/zh active Pending
- 2016-08-05 PE PE2018000178A patent/PE20180695A1/es unknown
- 2016-08-05 DK DK16750766.4T patent/DK3331900T3/da active
- 2016-08-05 CA CA2994771A patent/CA2994771C/en active Active
- 2016-08-05 EP EP20216899.3A patent/EP3854801A3/en active Pending
- 2016-08-05 MA MA41879A patent/MA41879A1/fr unknown
- 2016-08-05 CR CR20200431A patent/CR20200431A/es unknown
- 2016-08-05 MX MX2018001421A patent/MX2018001421A/es unknown
- 2016-08-05 EP EP20216870.4A patent/EP3842446A1/en active Pending
- 2016-08-05 UA UAA201800448A patent/UA125816C2/uk unknown
- 2016-08-05 RS RS20210446A patent/RS61713B1/sr unknown
- 2016-08-05 ES ES16750766T patent/ES2862400T3/es active Active
- 2016-08-05 MA MA053452A patent/MA53452A/fr unknown
- 2016-08-05 CR CR20200433A patent/CR20200433A/es unknown
- 2016-08-05 US US15/229,970 patent/US9908920B2/en active Active
- 2016-08-05 CR CR20200432A patent/CR20200432A/es unknown
- 2016-08-05 JP JP2018505723A patent/JP6884752B2/ja active Active
- 2016-08-05 KR KR1020187005514A patent/KR20180035845A/ko not_active Application Discontinuation
- 2016-08-05 EA EA201890440A patent/EA201890440A1/ru unknown
- 2016-08-05 SG SG10202001660YA patent/SG10202001660YA/en unknown
- 2016-08-05 PL PL16750766T patent/PL3331900T3/pl unknown
- 2016-08-05 CR CR20200434A patent/CR20200434A/es unknown
- 2016-08-05 MA MA053680A patent/MA53680A/fr unknown
- 2016-08-05 CN CN202111376484.6A patent/CN114395013A/zh active Pending
- 2016-08-05 EP EP23216403.8A patent/EP4324472A2/en active Pending
- 2016-08-05 EP EP16750766.4A patent/EP3331900B1/en active Active
- 2016-08-05 LT LTEP16750766.4T patent/LT3331900T/lt unknown
- 2016-08-05 CR CR20180074A patent/CR20180074A/es unknown
- 2016-08-05 CR CR20200435A patent/CR20200435A/es unknown
- 2016-08-05 MD MDE20180586T patent/MD3331900T2/ro unknown
- 2016-08-05 SI SI201631144T patent/SI3331900T1/sl unknown
- 2016-08-05 BR BR112018001687-0A patent/BR112018001687A2/pt active Search and Examination
- 2016-08-05 AU AU2016303021A patent/AU2016303021B2/en active Active
- 2016-08-05 PT PT167507664T patent/PT3331900T/pt unknown
-
2017
- 2017-06-29 US US15/637,906 patent/US9993539B2/en active Active
- 2017-06-29 US US15/638,072 patent/US10155032B2/en active Active
- 2017-12-21 US US15/849,878 patent/US10500259B2/en active Active
-
2018
- 2018-01-24 ZA ZA2018/00513A patent/ZA201800513B/en unknown
- 2018-01-25 PH PH12018500189A patent/PH12018500189A1/en unknown
- 2018-02-01 MX MX2021015933A patent/MX2021015933A/es unknown
- 2018-02-04 IL IL257331A patent/IL257331A/en unknown
- 2018-02-05 CL CL2018000324A patent/CL2018000324A1/es unknown
- 2018-02-27 CO CONC2018/0002202A patent/CO2018002202A2/es unknown
- 2018-08-10 US US16/100,498 patent/US10383930B2/en active Active
- 2018-10-05 US US16/153,294 patent/US10238727B2/en active Active
- 2018-12-05 US US16/210,330 patent/US10376568B2/en active Active
-
2019
- 2019-04-16 US US16/385,225 patent/US10478480B2/en active Active
- 2019-04-16 US US16/385,221 patent/US10449238B2/en active Active
- 2019-07-10 US US16/507,375 patent/US10532091B1/en active Active
- 2019-08-27 US US16/552,873 patent/US10799569B2/en active Active
-
2020
- 2020-06-29 US US16/915,465 patent/US11058754B2/en active Active
- 2020-09-10 US US17/017,281 patent/US11065315B2/en active Active
- 2020-11-18 JP JP2020191407A patent/JP7142957B2/ja active Active
-
2021
- 2021-02-26 CY CY20211100164T patent/CY1123854T1/el unknown
- 2021-04-01 AU AU2021202059A patent/AU2021202059B2/en active Active
- 2021-04-01 AU AU2021202060A patent/AU2021202060B2/en active Active
- 2021-04-01 AU AU2021202057A patent/AU2021202057B2/en active Active
- 2021-04-01 AU AU2021202058A patent/AU2021202058B2/en active Active
- 2021-04-01 AU AU2021202056A patent/AU2021202056B2/en active Active
- 2021-05-06 HR HRP20210709TT patent/HRP20210709T8/hr unknown
- 2021-05-14 US US17/320,929 patent/US11786584B2/en active Active
- 2021-05-14 US US17/320,938 patent/US11826409B2/en active Active
- 2021-05-14 US US17/320,878 patent/US20210275653A1/en not_active Abandoned
- 2021-06-11 CL CL2021001545A patent/CL2021001545A1/es unknown
- 2021-06-11 CL CL2021001542A patent/CL2021001542A1/es unknown
- 2021-06-11 CL CL2021001543A patent/CL2021001543A1/es unknown
- 2021-06-11 CL CL2021001544A patent/CL2021001544A1/es unknown
- 2021-06-30 CL CL2021001744A patent/CL2021001744A1/es unknown
-
2022
- 2022-01-14 US US17/576,185 patent/US20220125902A1/en active Pending
- 2022-01-14 US US17/576,067 patent/US20220133870A1/en active Pending
- 2022-01-21 US US17/581,049 patent/US20220143162A1/en active Pending
- 2022-01-21 US US17/581,054 patent/US20220143163A1/en active Pending
- 2022-01-28 US US17/587,474 patent/US20220152171A1/en active Pending
- 2022-01-28 US US17/587,536 patent/US20220143164A1/en active Pending
- 2022-02-04 US US17/592,573 patent/US20220152175A1/en active Pending
- 2022-09-07 JP JP2022142129A patent/JP2022191218A/ja active Pending
- 2022-11-21 CL CL2022003264A patent/CL2022003264A1/es unknown
-
2023
- 2023-07-13 AU AU2023204661A patent/AU2023204661A1/en active Pending
- 2023-08-17 US US18/451,216 patent/US20240016908A1/en active Pending
- 2023-09-22 AU AU2023233214A patent/AU2023233214A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3331900T2 (ro) | Peptide și combinație de peptide pentru utilizare în imunoterapie împotriva cancerului de prostată și altor cancere | |
MD3317296T2 (ro) | Noi peptide și combinație de peptide pentru utilizare în imunoterapie împotriva cancerului ovarian și a altor cancere | |
MD3394084T2 (ro) | Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva cancerului glandei mamare și a altor cancere | |
MD3291830T2 (ro) | Noi peptide și combinații de peptide și eşafodaje ale acestora pentru utilizare în imunoterapie împotriva carcinomului colorectal (CCR) și a altor cancere | |
MD3322717T2 (ro) | Noi peptide și combinație de peptide pentru utilizare în imunoterapie împotriva cancerului ovarian epitelial și a altor cancere | |
PH12018500848A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
MD3430027T2 (ro) | Peptide pentru utilizare în imunoterapia împotriva cancerului pulmonar nemicrocelular și a cancerului pulmonar microcelular | |
PH12018500864A1 (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
EA201891116A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов рака | |
EA201891638A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака | |
EA202191027A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
EA201891994A1 (ru) | Лечение рака матки | |
EA201992416A1 (ru) | Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака | |
CR20200494A (es) | NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174) | |
MD3319985T2 (ro) | Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva cancerului esofagian și a altor cancere | |
MD3388075T2 (ro) | Noi peptide și combinații de peptide pentru utilizare în imunoterapia împotriva unor diverse tumori (SEQ ID 25 - MXRA5-003) | |
EA201892159A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии омл и других видов рака | |
MD3236985T2 (ro) | Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și altor cancere | |
EA202190465A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака | |
EA202190241A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии хлл и других видов рака | |
EA202190357A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов рака | |
EA201990755A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака |